WhatPeptide

CJC-1295 (No DAC)

CJC-1295 without DAC (also called Modified GRF 1-29) is a GHRH analog with a shorter half-life than the DAC version, making it preferred for mimicking pulsatile physiological GH release when administered with a GHRP. It is widely used in research and wellness contexts for GH optimization.

Moderate evidence Unregulated GH Secretagogue

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Half-life

Estimated ~30 minutes (extrapolated from sermorelin t½ ~11-12 min plus DPP-IV-resistant substitutions; no direct human PK study for no-DAC form)

Dosage range

100-300 mcg subcutaneously 1-3x daily (pulsatile protocol)

Administration

Subcutaneous injection

Research level

Moderate

How CJC-1295 (No DAC) works

CJC-1295 no-DAC binds and activates pituitary GHRH receptors, stimulating somatotroph cells to release GH in a pulsatile fashion that closely mirrors endogenous GHRH dynamics. Without the drug affinity complex, its half-life of approximately 30 minutes confines GH release to discrete pulses, reducing tachyphylaxis and blunting of the GH axis compared to long-acting analogs. Synergistic effects are observed when co-administered with a GHRP such as Ipamorelin.

Also known as: Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC

Research relevance

GH Boost
Strong research relevance 80
Muscle Growth
Moderate relevance 65
Anti-Aging & Longevity
Moderate relevance 55

Side effects & safety

Water retention Headache Flushing Injection site irritation Elevated IGF-1 — theoretical concern for cancer promotion with prolonged use Possible insulin resistance with chronic use

Contraindications

Active malignancy
Diabetic retinopathy
Pregnancy

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is CJC-1295 (No DAC)? +
CJC-1295 without DAC (also called Modified GRF 1-29) is a GHRH analog with a shorter half-life than the DAC version, making it preferred for mimicking pulsatile physiological GH release when administered with a GHRP. It is widely used in research and wellness contexts for GH optimization. Its mechanism of action is supported by moderate clinical and preclinical evidence.
What is CJC-1295 (No DAC) researched for? +
CJC-1295 (No DAC) has the strongest research relevance for GH Boost, Muscle Growth, Anti-Aging & Longevity. Evidence is supported by moderate clinical and preclinical evidence.
What are the side effects of CJC-1295 (No DAC)? +
Reported side effects include Water retention, Headache, Flushing, Injection site irritation, Elevated IGF-1 — theoretical concern for cancer promotion with prolonged use, Possible insulin resistance with chronic use. Key contraindications: Active malignancy; Diabetic retinopathy; Pregnancy.
Is CJC-1295 (No DAC) FDA approved? +
CJC-1295 (No DAC) is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.
How is CJC-1295 (No DAC) administered? +
CJC-1295 (No DAC) is typically administered via subcutaneous route. Researched dosage range: 100-300 mcg subcutaneously 1-3x daily (pulsatile protocol). Half-life: Estimated ~30 minutes (extrapolated from sermorelin t½ ~11-12 min plus DPP-IV-resistant substitutions; no direct human PK study for no-DAC form).

Explore similar peptides

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

MK-677

Moderate evidence

GH Secretagogue

An oral non-peptide ghrelin receptor agonist often discussed with GH peptides due to GH/IGF-1 stimulating effects. Placed on FDA Category 2 list (September 29, 2023) as 'Ibutamoren mesylate.'

Sermorelin

Strong evidence

GH Secretagogue

FDA-approved as GEREF for diagnosis and treatment of growth hormone deficiency in children (NDA 20-443, approved September 26, 1997). Voluntarily withdrawn from market June 2009 for commercial reasons — not for safety or efficacy concerns (Federal Register 78 FR 14095, March 4, 2013). Remains compoundable under Section 503A.

Tesamorelin

Strong evidence

GH Secretagogue

A stabilized GHRH analog approved for reduction of excess visceral fat in HIV-associated lipodystrophy.